title: Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer.
authors.forename: T
authors.initials: T
authors.lastname: Paulsen
authors.forename: T
authors.initials: T
authors.lastname: Aas
authors.forename: A L
authors.initials: AL
authors.lastname: Børresen
authors.forename: J E
authors.initials: JE
authors.lastname: Varhaug
authors.forename: P E
authors.initials: PE
authors.lastname: Lønning
authors.forename: L A
authors.initials: LA
authors.lastname: Akslen
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D015415:Biomarkers; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D011237:Predictive Value of Tests; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics; D014841:von Willebrand Factor / Q000032:analysis
chemical_list: D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D016159:Tumor Suppressor Protein p53; D014841:von Willebrand Factor; D004317:Doxorubicin